Research by NTT DATA underscores the importance of aligning GenAI strategies with business strategies in healthcare organisations. Over 80% of healthcare organisation leaders surveyed have a well-defined GenAI strategy, but only 40% see a strong alignment with their business strategy.
The report, titled ” GenAI: The Care Plan for Powering Positive Health Outcomes,” based on responses from 425 decision makers and influencers from healthcare organisations across 33 countries, also found that only 54% consider their GenAI capability to be high performing.
Key Findings
In the APAC region, 93% of healthcare decision-makers stated that GenAI is accelerating the development of new treatments and enhancing diagnostics. However, 69% cite a skills gap as a barrier to effectively working with GenAI.
Moreover, 89% of respondents in the regions are concerned about privacy violations, but only 40% are confident in their current cybersecurity measures.
Some 84% believe that the benefits and potential of GenAI outweigh the risks, and 68% plan to make significant investments in GenAI over the next two years.
“To achieve GenAI’s full potential in healthcare, organisations must align the technology to their business strategies, develop comprehensive workforce training, and implement multilayered governance strategies that prioritise people and keep humans in the loop,” said Sundar Srinivasan, head of healthcare, NTT DATA North America. “It’s vital to transparently show how the technology benefits patients by complementing human workers.”
Srinivasan added that AI systems must also be aligned with regulatory and clinical guidelines to support operating objectives, stating that “Success hinges on high data quality and establishing collaborative decision-making teams.”
